In September, a rash of stories appeared about a study contradicting the claim that a class of proteins called sirtuins might be a possible anti-aging cure. “Longevity genes challenged,” Nature declared. “Longevity Gene Debate Opens Trans-Atlantic Rift,” wrote Nicholas Wade at The New York Times. “New study debunks longevity link for GSK’s sexy sirtuins,” wrote John Carroll for Fierce Biotech, the online tabloid of the biotech industry. “Those sexy ‘fountain of youth’ studies on sirtuins …have failed to live up to the initial hype,” Carroll wrote.
Faced with the barrage of whiplash-inducing headlines, I could only ask, “Haven’t we been here before?”